Post by
prophetoffactz on Aug 24, 2022 2:36pm
"very enthusiastic"
Gilles is going into the anticipated opportunity defining events very enthusiastically anyways. One wonder how much he may already know given the timing.
"More specifically, we are very enthusiastic for the many opportunities which we expect have the potential to drive significant value, including the Phase 1 clinical trial with our newly developed avenanthramides pill formulation, the development of new chemical complexes as potential delivery systems for bioactives with alginate as a carrier, the development and assessment of yeast beta glucan as an immune booster and as a potential inhalable therapeutic for lung fibrotic diseases including COVID-19 conditions and the implementation of the intermediary scale level of the PGX processing unit in Edmonton,” concluded Mr. Gagnon."
Comment by
Ciao on Aug 25, 2022 7:42am
If one compares the tone in prior quarterly updates, the level of optimism has changed very positively in this latest report.